logo-loader
viewFSD Pharma

FSD Pharma announces US$20M offering to help fund research on lead drug candidate FSD-201

FSD said it plans to use the funds to continue its R&D program on FSD-201, an anti-inflammatory ultra-micronized-palmitoylethanolamide to treat coronavirus patients

FSD Pharma -
FSD may also use proceeds of the offering to finance future growth opportunities such as acquisitions and investments

FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE) has announced a US$20 million at-the-market offering to help fund research on its lead drug FSD-201, which may help treat coronavirus.

The Toronto-based company said Monday it entered into an equity distribution agreement on July 10 with AGP/Alliance Global Partners that could see it sell Class B subordinate voting shares for aggregate gross proceeds of up to US$20 million.

The shares will only be offered in the US and not in Canada, where the company trades on the Canadian Securities Exchange, according to a release.

READ: FSD Pharma wins FDA nod to design Phase 2a clinical trial of its lead candidate micro-PEA to treat coronavirus patients

All sales of Class B shares will be made by way of ordinary broker transactions on the Nasdaq at prevailing market prices or as otherwise decided by the company and AGP/Alliance.

In a statement, FSD said it plans to use the funds to continue advancement of its R&D program on its lead candidate FSD-201, or anti-inflammatory ultra-micronized-palmitoylethanolamide (PEA), to treat coronavirus (COVID-19) patients.

The company recently received permission from the US Food and Drug Administration (FDA) to submit an Investigational New Drug (IND) application for FSD-201. In June, FSD announced that a Phase 1 study of FSD201 found the drug “to be safe and well-tolerated." It is currently designing a Phase 2a clinical trial.

FSD may also use the proceeds of the offering to finance future growth opportunities, including acquisitions and investments, as well as capital expenditures and working capital or general corporate purposes.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: FSD Pharma

Price: 3.85 CAD

CSE:HUGE
Market: CSE
Market Cap: $49.98 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of FSD Pharma named herein, including the promotion by the Company of FSD Pharma in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

FSD Pharma says $10M in new capital is 'gratifying' as the firm makes...

FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE) CEO Raza Bokhari tells Proactive it has closed US$10 million in a registered direct offering. Bokhari says the offering comes as the Canadian company actively works to submit an Investigational New Drug Application to the FDA to use its FSD201 as a...

3 days, 16 hours ago

2 min read